Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
59M
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
36.8M
-
Shares change
-
+490K
-
Total reported value, excl. options
-
$385M
-
Value change
-
+$4.83M
-
Number of buys
-
30
-
Number of sells
-
-33
-
Price
-
$10.47
Significant Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q1 2022
80 filings reported holding CGEM - Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2022.
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.8M shares
of 59M outstanding shares and own 62.33% of the company stock.
Largest 10 shareholders include BIOIMPACT CAPITAL LLC (7.65M shares), BVF INC/IL (5.37M shares), CHI Advisors LLC (2.75M shares), VANGUARD GROUP INC (2.35M shares), BlackRock Inc. (1.83M shares), FMR LLC (1.63M shares), BAUPOST GROUP LLC/MA (1.54M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.44M shares), AMERICAN INTERNATIONAL GROUP, INC. (1.24M shares), and Nextech Invest AG (1.22M shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.